FDA Issues Sodium Chloride Recalls Over Contamination and Safety Concerns

Two medicine recalls were notified by the FDA in August as a result of elevated endotoxin levels and particle concerns. B. Braun Medical, a German manufacturer of pharmaceuticals and medical devices, recalled two batches of injectable 0.9% sodium chloride to American consumers due to possible fluid and particle leaks from the product's "E3 containers." The solution is used as a priming solution for haemodialysis treatments, to treat metabolic alkalosis, and to restore extracellular fluid. According to the corporation, it delivered the impacted batches to domestic distributors in the United States by error prior to finishing the necessary acceptance operations for embedded particulate matter.

A single batch of 0.9% sodium chloride injection containing heparin sodium is being withdrawn by Baxter International because of the possibility of high endotoxin levels. The injection, which is given to patients as an anticoagulant to keep their catheters open, may have a major negative impact on their health and may result in death or lethal shock. The business has not been notified of any adverse event reports related to the product withdrawal as of August 6.

Drug manufacturers have been compelled to recall their medications over the last year due to problems with labelling, potency, contamination fears, and other difficulties. In July, Endo USA issued a recall for a single batch of clonazepam pills because of a labelling error that led to the product cartons printing the wrong strength. Three batches of lidocaine HCI and sodium bicarbonate injectables from Pfizer's Hospira were recalled in October because vials may have included glass fragments.